FDA removes suicidal-ideation warning from GLP-1 receptor agonist labels
Following a comprehensive review of post-market data and clinical trial results, FDA requested removal of the suicidal behaviour and ideation warning from labelling for GLP-1 receptor agonist (GLP-1 RA) medications including semaglutide, liraglutide, and dulaglutide. The review found no causal evidence linking these drugs to suicidality.
On 13 January 2026, FDA requested removal ↗ of suicidal behaviour and ideation warnings from labelling for all GLP-1 receptor agonists (GLP-1 RAs) ↗, including semaglutide (Ozempic, Wegovy, Rybelsus — DailyMed ↗), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity). The warning had been added in 2023 while the agency investigated reports, but the completed review found no causal link.
What the review found
The FDA's review included data from large randomised controlled trials (SUSTAIN, LEADER, REWIND), post-marketing adverse event reports from FAERS ↗, and epidemiological studies. Across millions of patient-years of exposure, the incidence of suicidal ideation or behaviour in GLP-1 RA users was not higher than in matched controls on other diabetes or obesity therapies. The European Medicines Agency reached the same conclusion ↗ in 2024.
Why this matters
GLP-1 RAs are among the most widely prescribed drugs in the US. Semaglutide (PubChem) ↗ alone has tens of millions of users. An unfounded suicidality warning risked deterring patients from effective treatments for type 2 diabetes ↗ and obesity. Prescribers should review current labelling via DailyMed ↗ to confirm the updated language.
FAQ
What triggers an FDA label update?
Label updates can be triggered by post-market safety data from the FAERS database ↗, new clinical trial results, manufacturer-initiated reviews, or FDA-directed safety communications. The FDA can require label changes under 21 CFR 314.81 or negotiate them with manufacturers. See the FDA Safety-related Labeling Changes (SrLC) database ↗ for a full history.
Where is the updated label published?
Updated labels are published on DailyMed (NLM) ↗ and Drugs@FDA ↗. DailyMed is typically the most current source, as manufacturers submit label updates there directly.